New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
14:28 EDTCELGCelgene announces results from Phase III study of VIDAZA
Celgene International Sŕrl, a wholly-owned subsidiary of Celgene announced that results from AML-001, its phase III study of VIDAZA, azacitidine for injection, compared to conventional care regimens,CCR, in elderly subjects with newly-diagnosed acute myeloid leukemia were presented in a late-breaking abstract oral session at the 19th European Hematology Association annual congress. The study was presented by Pr. Hervé Dombret of the Hôpital Saint-Louis in Paris, France. In the global, multi-center, randomized, open-label pivotal study, patients at least 65 years old with newly diagnosed or secondary AML with > 30% bone marrow blasts were pre-selected to receive one of three regimens per investigator’s choice from intensive chemotherapy, low-dose Ara-C or best supportive care only. Patients then randomized to receive either azacitidine or their predetermined CCR . Median overall survival, OS, the primary endpoint of the study, was 10.4 months for patients receiving azacitidine compared to 6.5 months for patients receiving CCR, which did not achieve statistical significance.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
17:08 EDTCELGCelgene announces phase 2 Apremilast data
Subscribe for More Information
April 13, 2015
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information
April 7, 2015
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use